Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that it has invested in Pharma Start, a contract research organization (CRO), providing outsourced product development services to pharmaceutical, biotechnology, and medical device companies. Terms of the transaction were not disclosed.
Pharma Start provides outsourced services including preclinical assessment, clinical development, clinical pharmacology, translational medicine, medical writing, and regulatory submission and lifecycle management in support of global pharmaceutical, biotechnology, and medical device companies.
Jim Cooper, Managing Partner, TSCP, said, “We’re pleased to combine the capabilities of Pharma Start and H2O Clinical. This partnership strengthens our ability to serve customers via an expanded menu of services. We are excited to continue growing this platform, while maintaining our businesses’ focus on industry-leading quality and customer service.”